ClinVar Miner

Submissions for variant NM_001330260.2(SCN8A):c.4850G>A (p.Arg1617Gln)

dbSNP: rs587777721
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology RCV000144154 SCV000297794 pathogenic Developmental and epileptic encephalopathy, 13 2016-07-14 criteria provided, single submitter research
GeneDx RCV000522954 SCV000616869 pathogenic not provided 2021-10-22 criteria provided, single submitter clinical testing Published functional studies demonstrate a damaging effect resulting in channel hyperactivity (Wagnon et al., 2016); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Missense variants in this gene are often considered pathogenic (HGMD); This variant is associated with the following publications: (PMID: 31692161, 25785782, 24194747, 26029160, 23020937, 24888894, 25568300, 25046240, 28554332, 29588952, 30171078, 28191890, 29655203, 32090326, 31175295, 33004838, 33442870, 26900580)
Labcorp Genetics (formerly Invitae), Labcorp RCV000636307 SCV000757746 pathogenic Early infantile epileptic encephalopathy with suppression bursts 2024-01-24 criteria provided, single submitter clinical testing This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 1617 of the SCN8A protein (p.Arg1617Gln). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with epileptic encephalopathies (PMID: 23020937, 24888894, 25046240, 25568300, 25785782, 26029160, 29588952). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 156106). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SCN8A protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects SCN8A function (PMID: 26900580). For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV001266283 SCV001444456 pathogenic Inborn genetic diseases 2018-01-04 criteria provided, single submitter clinical testing The p.R1617Q pathogenic mutation (also known as c.4850G>A), located in coding exon 26 of the SCN8A gene, results from a G to A substitution at nucleotide position 4850. The arginine at codon 1617 is replaced by glutamine, an amino acid with highly similar properties. This mutation was first identified in an individual with non-syndromic intellectual disability (Rauch A et al. Lancet, 2012 Nov;380:1674-82). It has also been reported in individuals with seizure disorders (Ohba C et al. Epilepsia, 2014 Jul;55:994-1000; Larsen J et al. Neurology, 2015 Feb;84:480-9; Kong W et al. Epilepsia, 2015 Mar;56:431-8; Dyment DA et al. Clin. Genet., 2015 Jul;88:34-40). In ND7/23 cells, this mutation causes elevated channel activity due to impaired channel inactivation (Wagnon JL et al. Ann Clin Transl Neurol, 2016 Feb;3:114-23). In addition, internal structural analysis indicates that this variant is part of a known motif needed for protein function and there are known pathogenic variants at equivalent positions in the protein (Spampanato J et al. J. Neurosci., 2004 Nov;24:10022-34; Mantegazza M et al. J. Neurosci., 2005 Mar;25:3341-9; Laezza F et al. Mol. Cell. Neurosci., 2009 Oct;42:90-101; Catterall WA. Neuron, 2010 Sep;67:915-28; Yan Z et al. Cell, 2017 Jul;170:470-482.e11). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
OMIM RCV000144154 SCV000189234 pathogenic Developmental and epileptic encephalopathy, 13 2014-07-01 no assertion criteria provided literature only
GeneReviews RCV000144154 SCV000298208 not provided Developmental and epileptic encephalopathy, 13 no assertion provided literature only
Clinical Molecular Genetics Laboratory, Johns Hopkins All Children's Hospital RCV000678845 SCV000805036 uncertain significance developmental delay with seizures 2017-08-25 no assertion criteria provided clinical testing
Channelopathy-Associated Epilepsy Research Center RCV003992195 SCV004809225 not provided Complex neurodevelopmental disorder no assertion provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.